Lanean...
Application of CRISPR/Cas9 Technology to HBV
More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI AG
2015-11-01
|
| Saila: | International Journal of Molecular Sciences |
| Gaiak: | |
| Sarrera elektronikoa: | http://www.mdpi.com/1422-0067/16/11/25950 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|